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DesumoylationAs the importance of ubiquitylation in certain disease states becomes increasingly apparent, the enzymes re-
sponsible for removal of ubiquitin (Ub) from target proteins, deubiquitylases (DUBs), are becoming attractive
targets for drug discovery. For rapid identiﬁcation of compounds that alter DUB function, in vitro assays must
be able to provide statistically robust data over a wide dynamic range of both substrate and enzyme concentra-
tions during high throughput screening (HTS). The most established reagents for HTS are Ubs with a quenched
ﬂuorophore conjugated to the C-terminus; however, a luciferase-based strategy for detecting DUB activity (DUB-
Glo™, Promega) provides a wider dynamic range than traditional ﬂuorogenic reagents. Unfortunately, this assay
requires high enzyme concentrations and lacks speciﬁcity for DUBs over other isopeptidases (e.g. desumoylases),
as it is based on an aminoluciferin (AML) derivative of a peptide derived from the C-terminus of Ub (Z-RLRGG-).
Conjugation of aminoluciferin to a full-length Ub (Ub-AML) yields a substrate that has awide dynamic range, yet
displays detection limits for DUBs 100- to 1000-fold lower than observed with DUB-Glo™. Ub-AML was even a
sensitive substrate for DUBs (e.g. JosD1 and USP14) that do not show appreciable activity with DUB-Glo™.
Aminoluciferin derivatives of hSUMO2 and NEDD8were also shown to be sensitive substrates for desumoylases
and deneddylases, respectively. Ub/Ubl-AML substrates are amenable to HTS (Z’=0.67) yielding robust signal,
and providing an alternative drug discovery platform for Ub/Ubl isopeptidases. This article is part of a Special
Issue entitled: Ubiquitin Drug Discovery and Diagnostics.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The complex and dynamic process of protein post-translational
modiﬁcation through the attachment and removal of ubiquitin (Ub)
impacts many cellular processes, including proteasome-mediated
degradation, DNA damage repair, and endocytic sorting of membrane
bound receptors [1–3]. Protein ubiquitylation can vary in the number
of sites in a single protein targeted for Ub conjugation, as well as the
number of Ub molecules attached at any one site, with long chains of
polyubiquitin (polyUb) being formed through the attachment of one
Ub molecule to another. These modiﬁcations vary in type and extent
from one target substrate to the next. Adding further combinatorialTS, high throughput screening;
CH, ubiquitin carboxyterminal
D8, nerounal precursor cell
inomethylcoumarin; Rho110,
biquitin Drug Discovery and
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ler).
rights reserved.power to this system is the potential for assembly of polyUb chains
with different functions through linkages at any of the seven lysines
(K6, K11, K27, K29, K33, K48, and K63) present in Ub [4], as well as
the N-terminus of the protein [5]. Heterogeneity can exist for polyUb,
as well, with “branched” chains being composed of linkages through
different lysines on the same Ub.
Considering this, it is not surprising that nearly 100 deubiquitylase
enzymes (DUBs) responsible for the removal of ubiquitin and/or polyUb
chains from proteins appear to exist in the human genome [6]. The
reader is referred to a number of excellent reviews that explore DUBs
inmore detail thanwill be donehere [7–9]. Brieﬂy, this class of enzymes
is typically divided into ﬁve families based on structural homology and/
or catalytic function. The ubiquitin C-terminal Hydrolase (UCH) family
of DUBs is characterized by efﬁcient cleavage of short peptides linked
to the C-terminus of Ub via isopeptide or standard peptide bonds.
Ubiquitin speciﬁc proteases (USPs), the largest family, are typically
found to catalyze the catabolism of iso-peptide bond linkages between
a Ub molecule and the target lysine. In addition to these two families,
there exist the ovarian tumor ubiquitin (OTU) domain and Machado–
Josephine domain (MJD) DUBs. These four DUB families are cysteine
proteases, with a canonical catalytic triad consisting of Cys, Asp, and
His residues. The ﬁfth DUB family, Jab1/MNP metalloenzyme (JAMM),
is unique in that it consists of metalloproteinases, requiring the co-
Scheme 1. Cleavage of Ub-AML through DUB action at the C-terminus liberates
aminoluciferin, a substrate for Photinus pyralis luciferase (ﬁreﬂy). This light producing
reaction provides large signal ampliﬁcation with near non-existent background.
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gation of substrate speciﬁcity for DUBs has mostly been carried out in
two ways, with traditional biochemical techniques attempting to dis-
cern the individual contributions of both polyUb chain topology type
and the target substrate to which it is covalently attached. More often,
though, DUBs are associated with a disease state through their dys-
regulation or genetic deletion in mouse models. While this may make
a DUB an attractive candidate for drug discovery, it is only through
extensive biochemical/biophysical characterization that it becomes a
viable one.
The combination of disease relevance and the critical mass of avail-
able investigative means has spurred increased interest within the
pharmaceutical industry to pursue DUBs as drug targets [10,11]. The
most precise methods for assessing DUB activity and speciﬁcity
rely on the analysis of polyUb chain cleavage by SDS-PAGE or liquid
chromatography–mass spectroscopy techniques (LC–MS), neither
of which are compatible with high throughput screening (HTS). In
order to rapidly identify potential medicinal compounds for either
antagonism or agonism of catalytic function, biochemical assays
must be developed that are amenable to both miniaturization and
automation, as well as provide data that are sensitive and statistically
robust with respect to variance.
Although a number of novel assaymethodologies, including the Ub-
CHOP reporter system [12,13] and a FRET-based LanthaScreen™ DUB
substrate (Life Technologies), have been developed to translate DUB ac-
tivity to HTS, the most widely used screening rationale for HTS is per-
haps the most simple: monomeric Ub linked at the C-terminus via an
amide bond to a ﬂuorophore such as amino-methylcoumarin (AMC)
or rhodamine 110 (Rho110) resulting in quenching of the ﬂuorophore
[14,15]. DUB amidohydrolase activity is monitored through the gain of
signal associated with liberation of the ﬂuorophore, with the modula-
tion of this signal in a signiﬁcant way being the criterion for identifying
lead compounds. Although this assay conﬁguration does not measure
isopeptidase activity (the hallmark ofmost DUBs) nor even peptidolytic
activity, due to its ease of use and convenience, it has been widely
adopted as a surrogate for these activities. In addition, there are a num-
ber of limitations inherent in the use of ﬂuorescence based Ub deriva-
tives. In the case of Ub-AMC, the spectral requirements of the assay
are especially problematic with respect to background, resulting in a
relatively narrowdynamic range. The use of Ub-Rho110 provides a con-
siderable improvement over Ub-AMC, due to the “red shift” in both ex-
citation and emission spectra; however, the limits of ﬂuorimetry still
place constraints on the useful concentration ranges of both the enzyme
and the substrate. The use of Ub-AMCor Ub-Rho110 could be precluded
if situations arise that require either low enzyme concentrations and/or
high substrate concentrations. This might occur during lead compound
optimization, for example, when inhibitor potency dictates lower en-
zyme concentrations so as not to approximate those of the inhibitor.
The recent emergence of a luminescence strategy demonstrated to
broadly detect activity of proteases that are responsible for the re-
moval of Ub/Ubl from target proteins, DUB-Glo™, is an alternative
to ﬂuorimetry with little to no detectable background signal [16,17].
The use of Photinus pyralis (ﬁreﬂy) luciferase in combination with
the substrate aminoluciferin has recently been adapted to measure
the activity of caspase proteases [18], based on the initial pioneering
work measuring the activity of chymotrypsin [19]. Since light is
only emitted when free aminoluciferin is in complex with luciferase,
and the molecule itself has no intrinsic luminescence, this molecule
is completely “dark” when conjugated to a peptide substrate
[17–19]. Reactions are virtually background-free, allowing greater
sensitivity at high substrate concentrations compared to ﬂuorogenic
substrates. Luciferase based protease assays are not without disad-
vantages, including the requirement of additional reagent compo-
nents (e.g. luciferase), the inability to determine Henri–Michaelis–
Menten kinetic constants, and the need to counter screen against
luciferase activity. Nevertheless, luciferin/luciferase technology canprovide a viable HTS platform through greatly enhanced sensitivity
where other readouts cannot.
DUB-Glo™ employs a peptide derived from the C-terminus of Ub
conjugated to aminoluciferin, (Z-RLRGG-AML) and has been demon-
strated to be compatible with measuring the activity of DUBs,
desumoylases, and deNEDDylases. Unfortunately, the use of this pep-
tide requires relatively high enzyme concentrations compared to full-
length Ub, consistent with the fact that this peptide is widely reported
to be a poor substrate for DUBs. Essentially, the increased dynamic
range of this assay is countered by the need for high enzyme concentra-
tions, potentially complicating downstream compound optimization as
mentioned above. This might be explained by the fact that Z-RLRGG-
AML does not (by deﬁnition) possess extended binding sites thought
to convey substrate speciﬁcity for DUBs [20]. These structural features
likely play a dominant role in favoring the cleavage of Ub by these en-
zymes over other Ub-like proteins, such as small ubiquitin-likemodiﬁer
(SUMO) [21] or neuronal precursor cell expressed developmentally
down-regulated 8 (NEDD8) [22]. The lack of these structural features
might also explain the utility of this substrate with a broad range of
Ub/Ubl proteases.
We hypothesized, then, that conjugation of aminoluciferin to a
full-length Ub (Ub-AML, Scheme 1), as opposed to a peptide derived
from its C-terminus (Z-RLRGG-AML), would result in a reagent dis-
playing the speciﬁcity and catalytic efﬁciency of full length ubiquitin
substrates (e.g. Ub-Rho110), as well as providing the robustness
and dynamic range typically observed for luciferin/luciferase assay
platforms, such as DUB-Glo™.
In order to investigate this hypothesis, comparative studies with
Ub-AML, DUB-Glo™, Ub-AMC, and Ub-Rho110 were carried out to
characterize this reagent as a substrate for a wide range of DUBs.
The additional ubiquitin-like (Ubl) molecule aminoluciferin deriva-
tives, human SUMO2 (hSUMO2-AML) and NEDD8 (NEDD8-AML),
were also generated and tested as analogous reagents for HTS in
desumoylation and deneddylation assays. Finally, Ub-AML was used
with a representative USP to simulate the process of assay develop-
ment and determine statistical robustness of this reagent in an HTS
campaign for this class of enzymes.
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2.1. Expression and puriﬁcation of Ub/Ubl-MESNa
DNA constructs containing human Ub (CAA44911), SUMO2
(NM_006937.3), and NEDD8 (NP_006147) cloned as C-terminal intein
fusions at Gly75 (pYTB, New England Biolabs) were generous gifts of
Dr. Keith Wilkinson (Emory University). Fusion proteins were
expressed (overnight, 18 °C) in BL21 (DE3pLysS) strain under the
IPTG inducible T7 promoter, and puriﬁed essentially as described
[15,23]. Brieﬂy, cell pellets were lysed (sonication) in cold 50 mM
HEPES, 50 mM sodium acetate, pH 6.5, 75 mM NaCl (HSS) containing
1 mM phenylmethylsulfonylﬂuoride (PMSF) and 5 mM benzamidine,
prior to clariﬁcation by high speed centrifugation. Soluble Ub/Ubl-intein
fusions were captured (4 °C) by chitin bead afﬁnity chromatography
(New England Biolabs), and subjected to “on-column” cleavage
(overnight, 4 °C) in the presence of 100 mM mecaptoethansulfonic
acid sodium salt (MESNa) at pH 6.5. Eluted protein was concentrated
and stored at−80 °C at pH 6.5. The precise concentration of an aliquot
of puriﬁed Ub-MESNa was determined by amino acid analysis, which
was then used to generate a calibration curve by RP-HPLC. All subse-
quent Ub/Ubl-MESNa and Ub/Ubl-AMLs were subjected (at least three
injection amounts) to RP-HPLC and liquid chromatography–mass spec-
troscopy (LC–MS), to determine molar concentrations, purity, and in-
tegrity. It was assumed that the contribution of the aminoluciferin
molecule contributed negligibly to these measurements.
2.2. Synthesis of Ub-AMC and Ub-Rho110
Ub-AMC and Ub-Rho110 were prepared through C-terminal con-
jugation of each ﬂuorophore to Ub-MESNa, essentially as previously
described for Ub-Rho110 [15]. Ub conjugates were puriﬁed (>95%)
by HPLC, lyophilized, and stored at −80 °C until use.
2.3. Generation of Ub/Ubl-AML substrates
2.3.1. Synthesis of glycyl-D-amino-luciferin
The synthesis of glycyl-D-amino-luciferin was essentially as previ-
ously described [24] with the intermediate 2-Cyano-6-amino-N-Boc-
glycine-benzothiazole being generated ﬁrst, followed by generation
of a chemically blocked form of glycine-D-aminoluciferin.
2.3.2. Synthesis of 2-Cyano-6-amino-N-Boc-glycine-benzothiazole
Commercially available Boc-Gly-OH (3.85 mmol) was dissolved in
18 mL CH2Cl2. Diisopropylcarbodiimide (3.9 mmol) and DMAP
(0.39 mmol) were added at 0° to the reaction, with stirring (0 °C)
for 20 min. 2-Cyano-6-aminobenzothiazole (2.57 mmol) was added
to the mixture and the reaction was stirred for an additional 3 h
(RT). The reaction was diluted with CH2Cl2 and washed with brine.
The organic layer was dried over anhydrous sodium sulfate, ﬁltered
and concentrated. The crude product was puriﬁed by preparative
RP-HPLC (Axia Gemini C18, 30×100 mm, Phenomenex, CA) using a
linear gradient of 10–90% AcN over 10 min with a ﬂow rate of
20 mL/min. After lyophilization, 2-Cyano-6-amino-N-Boc-glycine-
benzothiazole was obtained in 75% yield as a white solid and charac-
terized by LC–MS (Exact Mass: 332.0943).
2.3.3. Synthesis of Boc-glycine-D-aminoluciferin
2-Cyano-6-amino-N-Boc-glycine-benzothiazole (0.11 mmol) was
dissolved in 0.7 mL of dimethylformamide (DMF); H-D-cysteine-HCl
(0.12 mmol, dissolved in 0.1 mL of degassed water) was added drop-
wise to the organic solution, while protected from light. The mixture
was adjusted to pH 8.0 by addition of saturated K2CO3 in degassed
water, and the reaction was stirred for 1 h protected from light
(RT). Analytical LC–MS showed complete conversion to the product.
The crude reaction mixture was puriﬁed by preparative RP-HPLC asdescribed above. After lyophilization, Boc-glycyl-D-aminoluciferin was
obtained as a white solid in 80% yield and characterized by LC–MS
(Exact Mass: 436.0875).
2.3.4. Deprotection of glycyl-D-aminoluciferin
Boc-glycyl-D-aminoluciferin (0.2 M) was dissolved in a 1:1 mixture
of TFA:CH2Cl2 with 5% Et3SiH and allowed to stir for 1.5 h. The mixture
was concentrated under vacuum, and the residue was directly puriﬁed
by preparative RP-HPLC using a linear gradient of 0–45% AcN over
15 min with a ﬂow rate of 20 mL/min. After lyophilization, pure
glycyl-D-aminoluciferin was obtained as a light yellow solid in 90%
yield with mass determinations (LC–MS) consistent with those
predicted (Exact Mass: 336.0351).
2.3.5. Preparation and characterization of Ub/Ubl-AML substrates
Puriﬁed Ub/Ubl-MESNa was conjugated to glycyl-D-amino-luciferin
using amodiﬁed protocol for Ub-Rho110 that improved solubility of the
luciferin molecule and optimized conjugation efﬁciency. Ub-MES and
glycyl-D-aminoluciferin were mixed in a molar ratio of 1:100 in 2:1
DMF/DMSO, plus 2% triethylamine. The ﬁnal concentration of Ub-MES
was 0.5–1 mM. The reaction was monitored by LC–MS. After stirring
for 16 h (40 °C, protected from light), the conjugation was complete;
prolonged reaction time did not result in higher product yields. The
crude reaction mixture was puriﬁed by preparative RP-HPLC column
using a linear gradient of 20–50% AcN over 20 min at a ﬂow rate of
5 mL/min (Viva C18, 10×150 mm, Restek, PA). After lyophilization,
pure Ub (1–76)-aminoluciferin was obtained in 8–12% yield as a
white solid and characterized by LC–MS (See Fig. 1). The procedure
for the generation of additional Ubl-AML substrates was essentially
identical to one described above for Ub-AML. Ub/Ubl-AML purity was
typically >95% for each batch (Fig. 1). Lyophilized Ub/Ubl-AML sub-
strates were stored at −20 °C under desiccating conditions. They
were reconstituted in DMSO and the actual concentration was deter-
mined by RP-HPLC immediately prior to use.
2.4. Expression and puriﬁcation of Ub/Ubl proteases
The majority of Ub/Ubl proteases used in this study were expressed
in a BL21 strain of E. coli as either His-tagged proteins, or fusions to
SUMO or SUMOstar (LifeSensors, Inc). These proteases were puriﬁed
by a combination of immobilized metal afﬁnity chromatography
(IMAC) and size exclusion chromatography (SEC). They include: full-
length associated molecule with the SH3-domain of STAM (AMSHFL)
and the corresponding catalytic domain (AMSHcore), ADD05037;
Ataxin3, NP_004984.2; Ataxin3-like, NP_001129467.1; Deneddylase-1
(DEN1), NP_001159812.1; Josephin-1 (JosD1), NP_055691.1; Josephin-
2 (JosD2), NP_612207.1; Otubain-2, NP_075601.1; Sentrin/SUMO
Speciﬁc Protease 1 (SENP1), NP_055369.1, SENP2, NP_067640.2;
SENP6, NP_001093879.1; Ubiquitin C-terminal Hydrolase L3 (UCHL3),
NP_005993.1; UCHL5, NP_057068.1; catalytic domain of Ubiquitin-
Speciﬁc Protease 2 (USP2core), NP_004196.4; USP8, NP_001122082.1;
and USP14, NP_005142.1. Full-length forms of USP7 (NP_003461.2),
and USP20 (NP_001008563.2) were generated in a baculovirus expres-
sion system (BEVS), through the use of the Bac-to-Bac system (Life
Technologies), with recombinant viral characterization (titer) and pro-
tein production carried out in Spodoptera fugiperda (Life Technologies)
cells. Proteins were expressed intracellularly, and puriﬁed from soluble
insect extracts by IMAC. After puriﬁcation, all proteases were buffer ex-
changed into either 50 mM Tris or 20 mM HEPES (pH 7.5) containing
0.15 M NaCl, 2 mM DTT, and 10% glycerol. After buffer exchange and
concentration, proteins were aliquoted and stored at−80 °C until use.
Stock protein concentrations were determined by Bio Rad Protein
Assay (Bio Rad) relative to bovine serum albumin as a standard. In
some cases, protein concentration was also determined by absorbance,
using a calculated molar extinction coefﬁcient at 280 nm (Vector NTI).
Fig. 1. Physical characterization of Ub-AML by LC–MS. Themodiﬁied protein was analyzed by RP-HPLC (Restek Viva C18 column, 3 micron particle size, 2.1x150mm). The columnwas equil-
ibrated in 30%AcN/0.05% TFA at 0.2 mL/min anddevelopedwith a linear gradient to 50%AcN/0.05% TFAover 11min. The absorbance at 214 nm(upper panel, black line) of the efﬂuent from the
column was recorded prior to injection into the ionization chamber of an ESI/ToF mass spectrometer. The total ion chromatogram is shown as the dark gray line in the upper panel. The mass
spectrum (lower left panel) was extracted for the peak eluting at ~7 min and deconvoluted using the programMax Entropy to derive the parent mass spectrum shown in the lower left panel.
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All proteases were serially diluted into 50 mMHEPES, pH 7.5, 10 mM
DTT, 0.1% Prionex® (Sigma-Aldrich). In order to assess the reactivity of
the peptide substrate Z-RLRGG-AML to these enzymes, the substrate
was diluted into reconstituted DUB-Glo™ reagent (Promega, Inc.),
according to the manufactures' instructions. This included pre-
incubation for 30 min (RT, protected from light) in order to allow for
the consumption of any contaminating free D-aminoluciferin. For com-
parative studies, Ub/Ubl-AML substrates were substituted for Z-RLRGG-
AML and prepared in a similar manner. Reactions were assembled in
either 96- or low volume 384-well white plates, and luminescence was
monitored (EnVision Multi-label Plate Reader, Perkin Elmer) approxi-
mately 30 min post-DUB addition, unless otherwise noted. Reactions
were typically carried out in triplicate, with signal-to-background (S/B)
calculated by ﬁrst subtracting mean relative luminescence (RLU) in the
absence of enzyme (RLUbackground) from RLU in the presence of enzyme
(RLUsignal), then dividing by RLU in the absence of the enzyme so that
S/B=(RLUsignal−RLUbackground)/RLUbackground. RLU values used to deter-
mine (S/B)were taken fromprogress curve time points observed to be at
“steady-state” of light generation, ensuring appropriate relative compar-
isons across the plate. In most cases, RLUbackground was insigniﬁcant rela-
tive to the signal in the presence of the enzyme.
2.6. Assessment of Ub/Ubl protease activity with Ub-Rho110 and Ub-AMC
Ub-AMC and Ub-Rho110 (250 nM) were diluted into reaction
buffer consisting of 50 mM Tris, pH 8.0, 0.15 M NaCl, 5 mM DTT, and
0.05% CHAPS. Reactions were assembled in 96-well black plates,
and initiated by the addition of serially diluted DUBs. Fluorescence
intensity was monitored (30 min at intervals of 30 s) immediately
after DUB addition on an (EnVision Multi-label Plate Reader, PerkinElmer) using the excitation/emission ﬁlter pair of 340/460 nm for
Ub-AMC or 485/531 nm for Ub-Rho110.
3. Results and discussion
3.1. Ub-AML is a robust substrate with femtomolar limits of detection for
DUBs
Analysis of aminoluciferin conjugates by RP-HPLC determined by each
substrate was >95% pure. For each Ub/Ubl-AML substrate, determined
masses (Da) were found to be consistent with those predicted for conju-
gation products, and were as follows: Ub-AML, 8826.1 (calculated mass,
8826.2, Fig. 1); hSUMO2-LUC, 10,722.9 (calculated, 10,723.0); and
NEDD8-LUC, 8821.5 (calculated 8821.3).
The DUB-Glo™ system was used for the functional characterization
of Ub-AML, allowing independent comparison of Ub-AML to Z-
RLRGG-AML under identical assay conditions. The use of Ub-AML is
expected to be compatiblewith other luciferase/luciferin based systems
following user optimization. Fig. 2 illustrates representative RLU traces
for Ub-AML and Z-RLRGG-AML (Panels A and C, respectively), and cal-
culated (S/B) values for both substrates (Panels B and D, respectively).
The addition of UCHL3 to both Z-RLRGG-AML and Ub-AML was associ-
ated with increased luminescence over time. An initial “spike” of ob-
served light in the ﬁrst 30 min was followed by relatively prolonged
and steady light emission for more than an hour. This RLU signal trace
is typically indicative of “coupled” luminescence based protease assays,
where free aminoluciferinmust be liberated by catalysis [25]. Increased
signal intensity, at steady state light emission, for both substrates was
observed in a concentration-dependent manner for UCHL3. As previ-
ously demonstrated for Z-RLRGG-AML, then, reactions containing both
enzyme and Ub-AML resulted in the generation of free aminoluciferin
substrate as a product of Ub-AML cleavage. Although the dynamic
Fig. 2. Monitored progression of luminescence for Ub-AML and Z-RLRGG-AML. Increasing concentrations (indicated) of UCHL3 were incubated with either 500 nM Ub-AML (A) or
20 μM Z-RLRGG-AML(C) with immediate and continuous monitoring of luminescence (RLUs). Calculated S/B values (see methods) are shown for Ub-AML (B) and Z-RLRGG-AML
(D), with the dashed line drawn to illustrate S/B=3. Data are representative of triplicate measurements.
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ing this S/B for Z-RLRGG-AML required approximately 6000 timesmore
UCHL3 than for Ub-AML (compare legends for Fig. 2, Panels B and D),
revealing the extremely sensitive nature of Ub-AML relative to Z-
RLRGG-AML. Ub-AML and Z-RLRGG-AML were then tested in parallel
for assessing DUB activity with USP2core, USP7, USP8 and UCHL3 as a
reference control (Fig. 3, Panel A). Similar to previous reports with
UCHL3, the linear range for Z-RLRGG-AML was approximately 10- and
1000-fold above the no enzyme control. The detection range for this re-
agent allowed activity measurements for UCHL3 ranging from micro- to
nanomolar concentrations. In stark contrast, the use of Ub-AML resulted
in greatly decreased lower limits of detection for UCHL3 (S/B equal to
~6 at sub-femtomolar concentrations), with S/B values of 10 to 1000
over a dose response of at least three orders of magnitude. Similar results
were observed for USP2core and USP8, with a dynamic range for activity
measurements ranging fromapproximately nano- to femtomolar concen-
trations. To achieve a dynamic range comparable to Ub-AML, reactions
containing Z-RLRGG-AML required >1000-fold higher concentrations of
USP2core and USP8. For USP7, activity measurements with Ub-AML
yielded a linear dose response indistinguishable fromUSP8 andUSP2core.
However, comparisons between Ub-AML and Z-RLRGG-AML revealed aFig. 3. Determination of assay dynamic range for various DUB substrates. Panel A: Indicated
incubated with either 250 nM Ub-AML (closed symbols) or 20 μM Z-RLRGG-AML (open sym
Indicated concentrations of USP2core (♦/ ), USP7(●/ ), and USP8 (■/ ) were incubated
immediate and continuous monitored ﬂuorescence. S/B values were calculated from 30 mindramatic difference in the ability of these two substrates to assess USP7
activity. Even at micromolar concentrations of this DUB, Z-RLRGG-AML
was a very poor substrate, as S/B ratios did not reach 3. This difference
may likely be due to the requirement of full-length ubiquitin binding to
USP7 for full catalytic competency [26]. As with other DUBs [20,27],
USP7 binding to its substrate includes extended interactions away from
the catalytic site, with these interactions driving conformational changes
in the enzyme that ultimately lead to increased stability of a transition
state intermediate. These changes are not likely recapitulated through
binding of smaller, peptide substrates, such as Z-RLRGG-AML. By exten-
sion, the nature of the full length Ub-AML is also likely to contribute to
the increased sensitivity of this reagent for USP8 and USP2core as well.
Previous reports indicate that Z-RLRGG derivatives have a relatively
poor afﬁnity for DUBs [20] compared to full-length ubiquitin substrates
which would explain the requirement for much higher concentrations
of both enzyme and substrate in this assay. Although luciferin-based
assays preclude the dissection of individual kinetic parameters, differ-
ences in the overall kinetic efﬁciency between the two substrates should
manifest itself through these comparative studies. To highlight the contri-
butions of the luciferase/luciferin assay versus mechanistic differences in
substrate-enzyme recognition between Ub-AML and Z-RLRGG-AML, weconcentrations of UCHL3 (▲/ ), USP2core (♦/ ), USP7 (●/ ) and USP8 (■/ ) were
bols) for 30 min prior to RLU measurement and S/B calculation (see methods). Panel B:
with 250 nM of either Ub-AMC (closed symbols) or Ub-Rho110 (open symbols) with
time points (see methods). Data are representative of triplicate measurements.
Fig. 4. The use of Ub-AML with a panel of “difﬁcult-to-detect” DUBs. S/B determinations
(see methods) for indicated DUBs (10 nM) incubated with 250 nM Ub-AML (black
bars) or 20 μM Z-RLRGG-AML (white bars) for approximately 30 min prior to RLU mea-
surement. For reference, S/B values for these DUBs (10 nM) with Ub-AMC (250 nM,
30 min) are illustrated with gray bars.
Fig. 5. The use of hSUMO2- and NEDD8-AML for measuring isopeptidase activity. Panel
A: Indicated isopeptidases (50 nM to 70 pM) were incubated with hSUMO2-AML
(250 nM, black bars) or Z-RLRGG-AML (20 μM, white bars) for 30 min prior to RLU
measurement and S/B calculation according to methods. At 200 pM isopeptidase
(shown) hSUMO2-AML displays clear selectivity for desumoylases over DUBs. Error
bars indicate S.D. from triplicate measurements. Panel B: RLUs were measured from
NEDD8-AML (250 nM, black bars) or Z-RLRGG-AML (20 μM, white bars) after 30 min
incubation in either the presence or absence of 500 pM Den1.
2084 S.J. Orcutt et al. / Biochimica et Biophysica Acta 1823 (2012) 2079–2086compared these reagents to Ub-AMC and Ub-Rho110 (Fig. 3, Panel B). For
these substrates, S/B values of 3 to 40were observed at concentrations of
enzyme spanning 0.3 to 5 nM. Below this concentration range, signal did
not exceed background (data not shown). As expected, these reagents
possess lower limits of detection than found for DUB-Glo™, yet they do
not display both the sensitivity and dynamic range of Ub-AML. The en-
hanced sensitivity of Ub-AML compared to other substrates appears to re-
sult from the combinationof increased binding afﬁnity/catalytic efﬁciency
compared to Z-RLRGG, and the enhanced sensitivity of luciferase technol-
ogy overﬂuorogenic substrates. Perhaps themost important advantage of
increased sensitivity, from a drug discovery perspective, is the ability to
optimize substrate amounts in such a way as to increase the probability
of detecting inhibitormolecules at lower enzyme concentrations. In addi-
tion, the use of medicinal chemistry to increase compound potency cre-
ates the need for assays that provide adequate S/B at very low enzyme
concentrations. In any case, having the widest possible dynamic range
in an assay is beneﬁcial.
3.2. Ub-AML reveals DUB activity not detectable with Z-RLRGG-AML or
Ub-AMC
Although numerous reports exist of small molecule screening of iso-
peptidases with HTS amenable reagents [13,17,28,29], many DUBs re-
main relatively unexplored as drug discovery targets. Even though a
DUB may be described as active towards polyUb chains and/or in the
context of a cytosolic environment, the difﬁculty in translating this
activity (e.g. through SDS-PAGE or LC–MS) to HTS is obvious. In some
cases, even the use of luciferin based technology alone may not sufﬁce,
as Z-RLRGG-AML has been demonstrated to perform for only a subset of
these DUBs [16]. Given the apparent increased sensitivity and lower
limits of detection observed for Ub-AML over both Ub-AMC and Ub-
Rho110, we sought to test Ub-AML and Z-RLRGG-AML against a panel
of DUBs that typically yield low S/B for Ub ﬂuorogenic derivatives. A ti-
tration curve for each DUB (nano- to micromolar) was carried out
against Ub-AML and Z-RLRGG-AML in parallel. Each DUB was alsoTable 1
Platform comparison for various DUBs.1,2,3
Otub2 JosD1 JosD2 AMSH
Ub-AMC 1.2 1.1 2.1 1.0
Ub-Rho110 1.7 1.5 8.2 1.2
DUB-Glo™ 1.3 1.3 2.1 1.4
Ub-AML 9800 74 760 16
1 Signal-to-background = (maximum signal – background signal)/background, backgrou
2 DUB concentration equal to 10 nM.
3 [USP14]=330 nm.
4 N.D. = not determined.tested with Ub-AMC and Ub-Rho110 as reference substrates. For most
DUBs, achieving S/B levels greater than 3-fold with either Ub-AMC or
Z-RLRGG-AML required micromolar concentrations of enzyme (data
not shown). Strikingly, though, for Ub-AML all DUBs (with the excep-
tion of Ataxin3) tested at 10 nM yielded S/B ratios exceeding 10 after
30 min (Fig. 4 and Table 1). To our knowledge, this is the ﬁrst demon-
stration of a homogenous assay for many of these DUBs. USP14 has pre-
viously been shown to be active against Ub-AMC, but only in the
presence of afﬁnity-puriﬁed proteasomal machinery from human cells
[28]. Considering the enhanced sensitivity generally observed in these
studies with Ub-AML, it seemed possible that this reagent might detect
USP14 activity, even in the absence of proteasomal components. Re-
markably, a dose responsewas observed for this DUB, as well; although
higher concentrations of USP14 (approximately 300 nM) were re-
quired, S/B levels approached 10 after 2 h.
3.3. Demonstration of selectivity with hSUMO2- and NEDD8-AML
In order to provide additional Ubl-AML reagents for screening,
hSUMO2-AML and NEDD8-AML were generated and compared to Z-
RLRGG-AML. The use of hSUMO2-AML was associated with robust
S/B after 30 min for SENP1, SENP2, and SENP6 at 200 pM enzyme
(Fig. 5, Panel A). For SENP1 these S/B values were 10 to 50-fold higher
than Z-RLRGG-AML. Interestingly, this difference was not as large for
the other desumoylases tested, perhaps implying that SENP1 activity
might be more stringent in its requirement for extended substrate in-
teractions than either SENP2 or SENP6. As control reactions for speciﬁc-
ity, USP7 and USP8 were also tested for their ability to cleave hSUMO2-
AML. At 200 pM neither of these DUBs showed signiﬁcant signals for
the hSUMO2-AML, although activity was detected with Z-RLRGG-AML.
Both DUBs were tested at much higher concentrations (up to 50 nM)
to see if any cleavage was possible. No activity was detected for USP7;
however, for USP8 appreciable signals were observed at these higherAtaxin3 Ataxin3-like UCHL5 USP20 USP14
0.9 1.1 8.1 N.D.4 1.0
1.3 1.6 103 N.D. N.D.
1.3 1.5 1.4 2.9 2.0
4.0 120 1700 480 7.13
nd signal measured in the absence of DUB.
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tigated. To place this observation in context, though, comparable signals
when using Ub-AML required 50-fold lower concentrations of USP8. The
substrate NEDD8-AML also yielded higher signals than Z-RLRGG-AML
when used to measure the activity of DEN1 (Fig. 5, Panel B), demonstrat-
ing proof-of-concept for this substrate, as well. Taken together, the data
for hSUMO2- andNEDD8-AMLdemonstrate that these luciferin conjugat-
ed reagents are sensitive reagents for desumoylases anddeneddylases, re-
spectively, and demonstrate selectivity for Ub/Ubl-AML substrates.
It is conceivable that the selectivity observed for Ub/Ubl-AMLswould
be advantageous during Ub/Ubl protease drug discovery, presumably in
a manner analogous to Ub/Ubl-AMC or ‐Rho110. Given the extended in-
teractions away from the active site determined to exist between Ub/
Ubls and their cognate proteases [20–22,30], and the observation that
DUB conformation and/or catalytic competency is altered upon complex
formation with Ub [26], it stands to reason that the use of a full-length
Ub/Ubl substrate for HTS would provide the best chance for identifying
“hit” compounds during primary screening that might also demonstrate
selectivity for different isopeptidases. Although, Z-RLRGG-AML has been
demonstrated to have utility by displaying comparable reactivity across a
broad range of DUBs, desumoylases, and deneddylases [16], in certain
circumstances the ability to distinguish between the proteolytic activity
of Ub/Ubl proteases might be advantageous. It should be noted that
one report does exist in which an HTS campaign employing Z-RLRGG-
AMC was able to identify a viral protease inhibitor with apparent selec-
tivity at the P4 position [29]. Nevertheless, if enzyme speciﬁcity is not ob-
served with Z-RLRGG- based reagents, such as DUB-Glo™, it is possible
that the use of these reagents might be susceptible to the identiﬁcation
of inhibitors that lack selectivity, as well. Therefore, we suggest that
Ub/Ubl-AML provides a valuable alternative to DUB-Glo™ for determin-
ing Ub/Ubl protease activity through bioluminescence.3.4. Ub-AML is a robust reagent for HTS
We used Ub-AML to investigate a number of experimental parame-
ters that typically impact the decision to employ a given reagent for
HTS, including ﬂexibility, utility, cost, and robustness. The use of these
Ub/Ubl-AML substrates has been miniaturized to 30 μl in low volume,
384-well plates. Through the use of a representative USP, both enzyme
and Ub-AML concentrations were titrated to achieve assay parameters
in a manner similar to that shown for UCHL3 (Fig. 2). Optimal assay pa-
rameters were determined that 1) maximized assay window time at
“steady-state” of light generation, 2) established an acceptable S/Bwin-
dow, and 3)minimized reagent consumption. Under these conditions, a
representative sampling of assay plates were processed in the presence
(maximum signal, 3% DMSO) or absence (minimum signal) of DUB, and
the Z-factor [31] was calculated for the assay (Fig. 6). During this run,
fourteen independent 384-well plates were assayed after 1 h of incuba-
tion in the presence of the DUB. Overall S/B was determined to be 24-Fig. 6. Screening parameters for Ub-AML: RLUs for signal maximum (3% DMSO vehicle,
▲) and signal minimum (no enzyme, ●) were determined from (14) independent 384-
well plates. Overall S/B was determined to be 24-fold, with a Z-factor of 0.67, demon-
strating the robust nature of this assay format for screening isopeptidases.fold with a Z’=0.67, demonstrating the robust nature of Ub-AML for
HTS drug discovery.
4. Conclusions
Ub/Ubl-AML substrates yield enhanced sensitivity through luciferase/
luciferin biology, while mimicking the full length Ub/Ubl biological sub-
strate. Compared to Ub-AMC and Ub-Rho110 (e.g. UCHL3, USP2core),
Ub-AML (250–500 nM) displayed 100 to 1000-fold lower limits of detec-
tion for many DUBs, with S/B levels above 10 even with femtomolar
enzyme concentrations. The use of Ub-AML for a panel of DUBs
yielded S/B of 10 to 500 with nanomolar concentrations of enzyme,
while these DUBs did not yield appreciable activity with Ub-AMC,
Ub-Rho110, or DUB-Glo™. Notably, USP14 activity (S/B=5 to 10 at
300 nM) can be detected, even in the absence of additional proteosomal
components. Thus, this reagent provides the potential for a homoge-
nous in vitro assay for some DUBs for the ﬁrst time. The generation of
hSUMO2- and NEDD8-AML allowed the detection of Ub/Ubl protease
activity that is not only sensitive, but also selective for its respective
Ub/Ubl protease. Ub/Ubl-AML reagents are amenable tominiaturization
and automation, with a Z factor of >0.6 being determined for Ub-AML.
Ub/Ubl-AML substrates display enhanced sensitivity and ﬂexibility
compared to Ub-AMC and ‐Rho110,while providing a powerful alterna-
tive to DUB-Glo™ by providing a full length substrate displaying up to
1000-fold lower limits of detection for Ub/Ubl protease activity.
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